Do analysts prefer SLGL or DRCT?

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 172.79%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SLGL or DRCT?

In the previous week, Sol-Gel Technologies had 6 more articles in the media than Direct Digital. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 3 mentions for Direct Digital. Sol-Gel Technologies' average media sentiment score of 0.93 beat Direct Digital's score of 0.76 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Direct Digital 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HELP or SLGL?

In the previous week, Sol-Gel Technologies had 4 more articles in the media than Cybin. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 5 mentions for Cybin. Sol-Gel Technologies' average media sentiment score of 0.93 beat Cybin's score of 0.86 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SGP or SLGL?

In the previous week, Sol-Gel Technologies had 7 more articles in the media than Spyglass Pharma. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 2 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.46 beat Sol-Gel Technologies' score of 0.93 indicating that Spyglass Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SLGL or ARDX?

In the previous week, Ardelyx had 14 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 23 mentions for Ardelyx and 9 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.93 beat Ardelyx's score of 0.05 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 2 Very Positive mention(s) 2 Positive mention(s) 15 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Sol-Gel Technologies (SLGL) Competitors

$68.30 -4.10 (-5.66%)

Closing price 04:00 PM Eastern

Extended Trading

$68.11 -0.19 (-0.28%)

As of 07:30 PM Eastern

Compare

SLGL vs. DRCT, TRAW, HELP, SGP, and ARDX

Should you buy Sol-Gel Technologies stock or one of its competitors? Sol-Gel Technologies's main competitors and comparable companies include Direct Digital (DRCT), Traws Pharma (TRAW), Cybin (HELP), Spyglass Pharma (SGP), and Ardelyx (ARDX). Companies are selected based on similarities in market, industry, and size.

How does Sol-Gel Technologies compare to Direct Digital?

Sol-Gel Technologies (NASDAQ:SLGL) and Direct Digital (NASDAQ:DRCT) are related small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Sol-Gel Technologies has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Direct Digital has a beta of 5.33, suggesting that its stock price is 433% more volatile than the broader market.

Direct Digital has a net margin of -74.38% compared to Sol-Gel Technologies' net margin of -910.14%. Direct Digital's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Direct Digital	-74.38%	N/A	-68.48%

Sol-Gel Technologies has higher earnings, but lower revenue than Direct Digital. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.21	-$6.13M	-$5.64	N/A
Direct Digital	$30.91M	0.01	-$18.95M	-$156.85	N/A

Sol-Gel Technologies currently has a consensus price target of $197.50, suggesting a potential upside of 172.79%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 4.0% of Direct Digital shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 25.6% of Direct Digital shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sol-Gel Technologies had 6 more articles in the media than Direct Digital. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 3 mentions for Direct Digital. Sol-Gel Technologies' average media sentiment score of 0.93 beat Direct Digital's score of 0.76 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Direct Digital	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sol-Gel Technologies beats Direct Digital on 12 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Traws Pharma?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.21	-$6.13M	-$5.64	N/A
Traws Pharma	$2.79M	2.29	$9.17M	-$1.74	N/A

Sol-Gel Technologies has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

In the previous week, Sol-Gel Technologies had 8 more articles in the media than Traws Pharma. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 1 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 1.82 beat Sol-Gel Technologies' score of 0.93 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sol-Gel Technologies	Positive
Traws Pharma	Very Positive

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Sol-Gel Technologies presently has a consensus target price of $197.50, suggesting a potential upside of 172.79%. Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 140.38%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Sol-Gel Technologies beats Traws Pharma on 11 of the 17 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Cybin?

Cybin (NASDAQ:HELP) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Sol-Gel Technologies has higher revenue and earnings than Cybin. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Sol-Gel Technologies	$19.39M	12.21	-$6.13M	-$5.64	N/A

Cybin has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

Cybin has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Cybin currently has a consensus price target of $46.33, suggesting a potential upside of 320.07%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 172.79%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts plainly believe Cybin is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Sol-Gel Technologies had 4 more articles in the media than Cybin. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 5 mentions for Cybin. Sol-Gel Technologies' average media sentiment score of 0.93 beat Cybin's score of 0.86 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.9% of Cybin shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Sol-Gel Technologies beats Cybin on 10 of the 16 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Spyglass Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%

26.2% of Sol-Gel Technologies shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyglass Pharma presently has a consensus price target of $44.00, suggesting a potential upside of 76.99%. Sol-Gel Technologies has a consensus price target of $197.50, suggesting a potential upside of 172.79%. Given Sol-Gel Technologies' higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Sol-Gel Technologies had 7 more articles in the media than Spyglass Pharma. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 2 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.46 beat Sol-Gel Technologies' score of 0.93 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sol-Gel Technologies has higher revenue and earnings than Spyglass Pharma. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Sol-Gel Technologies	$19.39M	12.21	-$6.13M	-$5.64	N/A

Summary

Sol-Gel Technologies beats Spyglass Pharma on 9 of the 14 factors compared between the two stocks.

How does Sol-Gel Technologies compare to Ardelyx?

Sol-Gel Technologies (NASDAQ:SLGL) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Sol-Gel Technologies has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.21	-$6.13M	-$5.64	N/A
Ardelyx	$407.32M	1.98	-$61.60M	-$0.22	N/A

Sol-Gel Technologies has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 172.79%. Ardelyx has a consensus target price of $13.90, indicating a potential upside of 330.34%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts plainly believe Ardelyx is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Ardelyx has a net margin of -12.35% compared to Sol-Gel Technologies' net margin of -910.14%. Ardelyx's return on equity of -36.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Ardelyx	-12.35%	-36.00%	-10.77%

In the previous week, Ardelyx had 14 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 23 mentions for Ardelyx and 9 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.93 beat Ardelyx's score of 0.05 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	2 Very Positive mention(s)	2 Positive mention(s)	15 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Ardelyx beats Sol-Gel Technologies on 10 of the 16 factors compared between the two stocks.

Get Sol-Gel Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLGL vs. The Competition

Export

Metric	Sol-Gel Technologies	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$237.04M	$12.38B	$7.27B	$13.21B
Dividend Yield	N/A	2.63%	2.52%	22.89%
P/E Ratio	-12.11	618.74	193.11	18.97
Price / Sales	11.52	744.73	561.77	81.05
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	8.34	9.20	10.71	6.03
Net Income	-$6.13M	$2.83B	$3.50B	$380.34M
7 Day Performance	-9.70%	-3.51%	-3.18%	-3.04%
1 Month Performance	3.58%	-6.19%	-6.61%	-5.16%
1 Year Performance	70.96%	-5.64%	3.69%	-2.48%

Sol-Gel Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLGL Sol-Gel Technologies	3.4947 of 5 stars	$68.30 -5.7%	$197.50 +189.2%	+85.7%	$237.04M	$19.39M	N/A	28
DRCT Direct Digital	1.2521 of 5 stars	$0.54 flat	N/A	-99.5%	$432K	$34.69M	N/A	73	News Coverage
TRAW Traws Pharma	2.143 of 5 stars	$0.52 -3.0%	$1.00 +92.3%	-86.2%	$7.99M	N/A	N/A	7
HELP Cybin	4.0646 of 5 stars	$10.76 -5.8%	$46.33 +330.6%	N/A	$847.67M	N/A	N/A	100
SGP Spyglass Pharma	3.0239 of 5 stars	$24.78 -3.2%	$44.00 +77.6%	N/A	$828.40M	N/A	N/A	65

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLGL) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, HELP, SGP, and ARDX

How does Sol-Gel Technologies compare to Direct Digital?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Summary

How does Sol-Gel Technologies compare to Cybin?

Summary

How does Sol-Gel Technologies compare to Spyglass Pharma?

Summary

How does Sol-Gel Technologies compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sol-Gel Technologies (SLGL) Competitors

SLGL vs. DRCT, TRAW, HELP, SGP, and ARDX

How does Sol-Gel Technologies compare to Direct Digital?

Which has more risk and volatility, SLGL or DRCT?

Is SLGL or DRCT more profitable?

Which has better valuation & earnings, SLGL or DRCT?

Do analysts prefer SLGL or DRCT?

Do insiders & institutionals have more ownership in SLGL or DRCT?

Does the media prefer SLGL or DRCT?

Summary

How does Sol-Gel Technologies compare to Traws Pharma?

Is SLGL or TRAW more profitable?

Which has better earnings & valuation, SLGL or TRAW?

Which has more risk and volatility, SLGL or TRAW?

Does the media prefer SLGL or TRAW?

Do insiders and institutionals have more ownership in SLGL or TRAW?

Do analysts rate SLGL or TRAW?

Summary

How does Sol-Gel Technologies compare to Cybin?

Which has preferable earnings & valuation, HELP or SLGL?

Is HELP or SLGL more profitable?

Which has more volatility & risk, HELP or SLGL?

Do analysts prefer HELP or SLGL?

Does the media favor HELP or SLGL?

Do institutionals & insiders have more ownership in HELP or SLGL?

Summary

How does Sol-Gel Technologies compare to Spyglass Pharma?

Is SGP or SLGL more profitable?

Do insiders and institutionals have more ownership in SGP or SLGL?

Do analysts prefer SGP or SLGL?

Does the media prefer SGP or SLGL?

Which has better earnings and valuation, SGP or SLGL?

Summary

How does Sol-Gel Technologies compare to Ardelyx?

Which has stronger earnings & valuation, SLGL or ARDX?

Which has more risk & volatility, SLGL or ARDX?

Do analysts recommend SLGL or ARDX?

Is SLGL or ARDX more profitable?

Does the media refer more to SLGL or ARDX?

Do insiders & institutionals believe in SLGL or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLGL vs. The Competition

Sol-Gel Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools